Financial Summary

Biogen Inc  (BIIB)  $246.92    (%)

  • Symbol
    BIIB
    Price
    246.92$
    Beta
    0.56693
    Volume Avrg.
    1652987
    Market Cap
    37996544000
    Last Div
    0
    Range
    223.25-374.99
    Changes
    3.76
    Changes Percentage
    Exchange
    Nasdaq Global Select
    Industry
    Drug Manufacturers General
    Ceo
    Mr. Michel Vounatsos
    Sector
    Healthcare

About company

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.


Income Statement

YearRevenueCost of revenuesGross profitOperating expensessOperating incomesInterest expenseIncome tax expensesEarnings before taxsNet incomeEarnings per share basicsEarnings per share dilutedsDividend per sharesGross marginsEBIT marginsProfit marginsEBITDAEBITEarnings Before Tax MarginsNet Profit Margins
2020220747.00 151286.00 104956.00 38668.0066288.002873.00968.0067091.0057411.003.308587268217793.280.8033334143460.4754583301250.3002894716580.26007601462377344.0066288.000.3039271201870.260076014623
2019260174.00 161782.00 98392.00 34462.006393.003576.0010481.0065737.0055256.0011.9711.893.037054038220.378177681090.2457201718850.2123809450676477.006393.000.2526655238420.21238094506
2018265595.00 163756.00 101839.00 30941.0070898.00324.0013372.0072903.0059531.0012.0111.912.742340216980.38343718820.2669402661950.22414202074681801.0070898.000.2744893540920.224142020746
2017229234.00 141048.00 88186.00 26842.0061344.002323.0015738.0064089.0048351.009.279.212.431406868490.3846986049190.2676042820870.21092420845171501.0061344.000.2795789455320.210924208451
2016215639.00 131376.00 84263.00 24239.0060024.001456.0015685.0061372.0045687.008.358.312.208978050390.3907595564810.2783541010670.21186798306470529.0060024.000.2846052893960.211867983064
2015233715.00 140089.00 93626.00 22396.007123.00733.0019121.0072515.0053394.009.289.221.995660676580.4005990201740.3047729071730.22845773698782487.007123.000.3102710566290.228457736987
2014182795.00 112258.00 70537.00 18034.0052503.00384.0013973.0053483.003951.006.496.451.8171831440.3858803577780.2872233923250.21614376760960449.0052503.000.2925845892940.216143767609
201317091.00 106606.00 64304.00 15305.0048999.00136.0013118.0050155.0037037.0040.0339.7511.3388761160.3762448072080.2866947516240.21670469837955756.0048999.000.2934585454330.216704698379
2012156508.00 87846.00 68662.00 13421.0055241.000.001403.0055763.0041733.0044.6444.152.631815561350.4387123980880.352959593120.26665090602458518.0055241.000.3562948858840.266650906024
2011108249.00 64431.00 43818.00 10028.003379.000.008283.0034205.0025922.0028.0527.680.00.4047889587890.3121506896140.23946641539435604.003379.000.3159844432740.239466415394
201065225.00 39541.00 25684.00 7299.0018385.000.004527.001854.0014013.0015.4115.150.00.3937753928710.2818704484480.21484093522419412.0018385.000.2842468378690.214840935224
200942905.00 25683.00 17222.00 5482.001174.000.003831.0012066.008235.001.3171.2970.00.40140.28120.192128.0012066.000.28120.1919
Year202020192018201720162015201420132012201120102009
Revenue220747.00260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues151286.00161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 104956.00 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess38668.0034462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense2873.003576.00324.002323.001456.00733.00384.00136.000.000.000.000.00
Income tax expenses968.0010481.0013372.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs67091.0065737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income57411.0055256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics3.3085872682177911.9712.019.278.359.286.4940.0344.6428.0515.411.317
Earnings per share diluteds3.2811.8911.919.218.319.226.4539.7544.1527.6815.151.297
Dividend per shares0.83.042.742.432.2121.8211.342.63000
Gross margins0.480.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.30.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.260.210.220.210.210.230.220.220.270.240.210.19
EBITDA77344.0076477.0081801.0071501.0070529.0082487.0060449.0055756.0058518.0035604.0019412.00128.00
EBIT66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.30.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.260.210.220.210.210.230.220.220.270.240.210.19